Palisade Bio
PALI
4 hedge funds and large institutions have $49.5M invested in Palisade Bio in 2014 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
324% more capital invested
Capital invested by funds: $11.7M → $49.5M (+$37.8M)
300% more funds holding
Funds holding: 1 → 4 (+3)
260% more call options, than puts
Call options by funds: $324K | Put options by funds: $90K
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$12.4M |
| 2 |
FAM
Fred Alger Management
New York
|
+$8.28M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$4.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$229K |
| 2 |
OC
Oppenheimer & Co
New York
|
-$29K |
| 3 |
WEC
Winslow Evans & Crocker
Boston,
Massachusetts
|
-$9K |
| 4 |
Citigroup
New York
|
-$6K |
PALI Hedge Fund Activity: Q1 2014 in Review
4 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2014, worth a combined $49.5M — up 324% from $11.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PALI positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Putnam Investments, opening a new position worth an estimated $12.4M. The largest seller was Virtu KCG Holdings, cutting an estimated $229K.
- 4 institutional investors held Palisade Bio (PALI) as of Q1 2014, up from 1 in Q4 2013.
- Funds reported $49.5M of Palisade Bio stock for Q1 2014, up 324% quarter-over-quarter.
- 3 funds opened new Palisade Bio positions in Q1 2014 and 0 closed out, a net change of +3 holders.
- The largest Palisade Bio buyer in Q1 2014 was Putnam Investments, an estimated $12.4M added.
- The largest Palisade Bio seller in Q1 2014 was Virtu KCG Holdings, an estimated $229K sold.
Based on aggregated 13F filings for Q1 2014.